{"entity":{"id":"nct06425926","kind":"trial","name":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of GIM-531 in melanoma, run by Georgiamune Inc, now recruiting.","summary":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06425926 by Georgiamune Inc, with 117 participants planned, started 2024-05-09 and due to reach its primary completion in 2026-12. Interventions recorded: GIM-531 and Anti-PD-1 monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06425926","url":"https://clinicaltrials.gov/study/NCT06425926"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["georgiamune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06425926","phase":"1/2","setting":"A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors","sponsor":"Georgiamune Inc","enrolled":117,"outcomes":[]},"route":"/trials/nct06425926/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/"}]}}